Loading...

GLMD

GLMD

GALMED PHARMACEUTICALS LTD

(GLMD)

2025 6-K

Shareholder Meeting Held

5 Mar '26

Shareholder Meeting Update

4 Mar '26

Shareholders Meeting

9 Feb '26

Nasdaq Letter Received

30 Jan '26

Research Presentation

8 Dec '25

Patent Grant Announcement

4 Dec '25

CEO Letter Issued

1 Dec '25

Q3 Financial Update

26 Nov '25

Study Results Announced

18 Nov '25

Study Results Report

17 Nov '25

Annual Meeting Results

29 Oct '25

Meeting Adjourned

28 Oct '25

Annual Meeting Announcement

19 Sep '25

Financial Results Update

28 Aug '25

Digital Asset Strategy

25 Aug '25

Shareholder Meeting Result

15 Aug '25

Shareholder Meeting Update

14 Aug '25

Shareholder Meeting

24 Jul '25

Biomarker Discovery

27 May '25

Quarterly Financial Results

22 May '25

Anti-Fibrotic Effects

13 May '25

Oncology Study Results

6 May '25

Development Agreement

28 Apr '25

Collaboration Announcement

17 Apr '25

Novel Blood Markers

15 Apr '25

Positive Study Results

10 Apr '25

Patent Extension Granted

20 Mar '25

Sales Agreement

14 Nov '24

Financial Update

14 Nov '24

Shareholder Meeting Result

21 Oct '24

Shareholder Meeting Update

15 Oct '24

Clinical Trial Results

25 Sep '24

Shareholder Meeting

20 Sep '24

Expansion Announcement

19 Sep '24

Compliance Regained

16 Sep '24

Equity Purchase Agreement

30 Aug '24

Financial Update

28 Aug '24

Share Consolidation

27 Aug '24

Shareholder Meeting

18 Jul '24

Annual Meeting Adjourned

11 Jul '24

Annual Meeting Notification

5 Jun '24

Quarterly Report

30 May '24

NASDAQ Compliance Notice

19 Mar '24

Patent Announcement

15 Mar '24

External Links:

SEC

On December 4, 2025, Galmed Pharmaceuticals Ltd. announced the grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals' Resmetirom for the treatment of MASH. This represents a significant advancement for the company and its product pipeline.

AI Assistant

GALMED PHARMACEUTICALS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.